Mutational signatures and their association with survival and gene expression in urological carcinomas.

Different sources of mutagenesis cause consistently identifiable patterns of mutations and mutational signatures that mirror the various carcinogenetic processes. We used publicly available data from the Cancer Genome Atlas to evaluate the associations between the activity of the mutational signatures and various survival endpoints in six types of urological cancers after adjusting for established prognostic factors. The predictive power of the signatures was evaluated with dynamic area under curve models. In addition, links between mutational signature activities and differences in gene expression patterns were analysed. APOBEC-related signature SBS2 was associated with improved overall survival (OS) and disease-specific survival (DSS) in bladder carcinomas in the multivariate analysis, while clock-like signature SBS1 predicted shortened DSS and progression-free interval (PFI) in clear cell renal cell carcinomas (ccRCC). In papillary renal cell carcinomas (pRCC), SBS45 was a predictor of improved outcomes, and APOBEC-related SBS13 was a predictor of worse outcomes. Gene expression analyses revealed various enriched pathways between the low- and high-signature groups. Interestingly, in both the ccRCC and pRCC cohorts, the genes of several members of the melanoma antigen (MAGE) family were highly upregulated in the signatures, which predicted poor outcomes, and downregulated in signatures, which were associated with improved survival. To summarize, SBS signatures provide substantial prognostic value compared with just the traditional prognostic factors in certain cancer types. APOBEC-related SBS2 and SBS13 seem to provide robust prognostic information for particular urological cancers, maybe driven by the expression of specific groups of genes, including the MAGE gene family.

Anticancer efficacy of lupeol incorporated electrospun Polycaprolactone/gelatin nanocomposite nanofibrous mats.

Despite the anticancer effect of lupeol (Lup), low aqueous solubility can make its therapeutic usage difficult. However, polycaprolactone/Gelatin (PCL-GEL) nanofibers scaffold eliminates this problem. This study has been conducted to recognize PCL-GEL-Lup nanofibers effect on cancer cell lines. PCL-GEL solution was prepared at different ratios (8 wt% and 4 wt%) for achieving optimal nanofibers. PCL-GEL-Lup nanofibers were provided via electrospinning technique. The surface morphology of nanofibers was examined using FESEM. Functional groups were investigated by a Fourier Transform Infrared spectroscopy. Lupeol released from nanofibers was detected by a UV-Visible spectroscopy. The drug release profile confirmed the sustained release of about 80% achieved within 40 h. IC50of lupeol against ACHN and HSC-3 cell lines are 52.57 and 66.10µg ml-1respectively. The study results from aid an understanding of the fabrication of a scaffold with an optimum dose of bioactive lupeol in 6 wt% with bead free uniform diameter that is capable of binding the drug efficiently. The enhanced cytotoxicity activity by effective diffusion and elution to the target achieved in this study help to develop a nanofiber in the ongoing battle against cancer.

[Circumferential calcifications in cromophobe renal cell carcinoma: Description of a clinical case and review of the literature.] / Calcificaciones anormales en tumor renal de células cromófobas: descripción de un caso clínico y revisión de la literatura.

We present a clinical case of an asymptomatic 61-year-old man was found to have a left kidney mass. Ultrasound and CT showed a 6 x 5 cms mass with calcifications. Histologic examination of the radical nephrectomy specimen revealed a chromophobe renal cell carcinoma. The unique feature of this case is the type of calcifications present in a tumor of this category. To our knowledge, were port the first case of chromophobe renal cell carcinoma with peripheral linear calcifications. A literature review onchromophobe renal cell carcinoma with calcifications is performed.

Presentamos el caso de un varón de 61 años diagnosticado de forma incidental de una tumoración renal izquierda. Las imágenes radiológicas obtenidas mediante ecografía y TAC muestran una masa de 6 x 5 cms con calcificaciones circunferenciales y periféricas. El estudio anatomopatológico de la pieza de nefrectomía radical evidencia un carcinoma renal de células cromófobas. La peculiaridad de este caso reside en el tipo de calcificaciones presentes en un tumor de este tipo no habiéndose descrito previamente, en nuestro conocimiento, calcificaciones lineales periféricas como éstas, en carcinoma renal de células cromófobas. Realizamos una revisión de la literatura acerca de las calcificaciones en carcinoma renal de células cromófobas.

Calcificaciones anormales en tumor renal de células cromófobas: descripción de un caso clínico y revisión de la literatura / Abnormal calcifications in a renal chromophobe cell tumor: description of a clinical case and review of the literature

Presentamos el caso de un varón de 61 añosdiagnosticado de forma incidental de una tumoración re-nal izquierda. Las imágenes radiológicas obtenidas me-diante ecografía y TAC muestran una masa de 6 x 5 cmscon calcificaciones circunferenciales y periféricas. El estu-dio anatomopatológico de la pieza de nefrectomía radicalevidencia un carcinoma renal de células cromófobas. Lapeculiaridad de este caso reside en el tipo de calcifica-ciones presentes en un tumor de este tipo no habiéndosedescrito previamente, en nuestro conocimiento, calcifica-ciones lineales periféricas como éstas, en carcinoma renalde células cromófobas. Realizamos una revisión de la lite-ratura acerca de las calcificaciones en carcinoma renal decélulas cromófobas.(AU)

We present a clinical case of an asymptom-atic 61-year-old man was found to have a left kidney mass.Ultrasound and CT showed a 6 x 5 cms mass with calcifi-cations. Histologic examination of the radical nephrectomyspecimen revealed a chromophobe renal cell carcinoma.The unique feature of this case is the type of calcificationspresent in a tumor of this category. To our knowledge, wereport the first case of chromophobe renal cell carcinomawith peripheral linear calcifications. A literature review onchromophobe renal cell carcinoma with calcifications isperformed.(AU)

The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma.

PURPOSE: The role of 68Ga-PSMA PET/CT in the staging of prostate cancer is well known. PSMA is also overexpressed in the neovasculature of other tumours including renal cell carcinoma (RCC), suggesting there may be a role for the use of 68Ga-PSMA PET/CT. Thus far, there has been limited literature documenting the use of 68Ga-PSMA PET/CT in the investigation and management decisions of RCC. METHODS: This was a retrospective case series of patients who received a 68Ga-PSMA PET/CT scan for staging or restaging of RCC between July 2016 and December 2018. Primary outcome measure was to identify whether 68Ga-PSMA PET/CT changed management compared to standard diagnostic CT imaging. Analysis was based on four categories: (1) identification of new disease, (2) refuting disease on CT imaging, (3) identification of synchronous primaries, and (4) concordance with CT imaging. RESULTS: 38 68Ga-PSMA PET/CT scans met inclusion criteria. Primary staging scans were performed in 16 patients, of which 75% showed avid primary lesions, with the majority of clear cell subtype. Management was changed in 43.8% of patients. CT agreed with 68Ga-PSMA PET/CT in 37.5% of cases. Restaging scans were performed in 22 patients. 40.9% of patients had management changed by results of 68Ga- PSMA PET/CT. CT agreed with 68Ga- PSMA PET/CT in 36.4% of cases. Management was predominantly changed due to the identification of new sites of suspected metastases, as well as the detection of synchronous primaries. CONCLUSIONS: 68Ga-PSMA PET/CT directly changed management in 42.1% of cases. Strongest detection rates occurred in those patients with clear cell RCC. The results of this study suggest there may be merit in the use of the modality in the staging of RCC. Further analysis, both with respect to histological confirmation, efficacy and cost-benefit, is required to determine whether there is a role for routine 68Ga-PSMA PET/CT imaging.